DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Colorectal Cancer
Enrolment: 188 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Colorectal Cancer
Enrolment: 188 · Results not recorded
Multiple Myeloma · Renal Insufficiency
Enrolment: 9 · Results not recorded
Biliary Tract Cancer
Enrolment: 15 · Results not recorded
Gastric Cancer · GastroEsophageal Cancer
Enrolment: 247 · Results not recorded
Endometrial Cancer
Enrolment: 8 · Results not recorded
Smoldering Multiple Myeloma
Enrolment: 41 · Results not recorded
Hepatocellular Carcinoma
Enrolment: 70 · Results not recorded
Metastatic Esophageal Cancer · Metastatic Gastric Cancer
Enrolment: 52 · Results not recorded
Multiple Myeloma
Enrolment: 8 · Results not recorded
Multiple Myeloma Bone Disease
Enrolment: 28 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: dextran sulfate sodium (DSS)-induced colitis
Reduced Dkk1 increased epithelial proliferation and accelerated recovery and wound repair after colitis.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.